A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer-Reference-Cited by-同舟云学术

A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer

Published:2021-08-10 Issue:18 Volume:10 Page:6354-6364
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Tsaur Igor¹^ORCID,Heidegger Isabel²,Bektic Jasmin²,Kafka Mona²,Bergh Roderick C. N.³,Hunting Jarmo C. B.³,Thomas Anita¹,Brandt Maximilian P.¹,Höfner Thomas¹,Debedde Eliott⁴,Thibault Constance⁴,Ermacora Paola⁵,Zattoni Fabio⁵,Foti Silvia⁶,Kretschmer Alexander⁷,Ploussard Guillaume⁸⁹^ORCID,Rodler Severin⁷,Amsberg Gunhild¹⁰,Tilki Derya¹¹¹²,Surcel Christian¹³,Rosenzweig Barak¹⁴,Gadot Moran¹⁵,Gandaglia Giorgio¹⁶,Dotzauer Robert¹,

Affiliation:

1. Department of Urology and Pediatric Urology University Medicine Mainz Mainz Germany

2. Department of Urology Medical University Innsbruck Innsbruck Austria

3. Department of Urology St Antonius Hospital Utrecht The Netherlands

4. Department of Medical Oncology European Georges Pompidou HospitalAssistance Publique des Hôpitaux de ParisParis Descartes University Paris France

5. Unit of Urology Santa Maria della Misericordia Academic Medical Center Hospital Udine Italy

6. Division of Oncology/Unit of Oncology Urological Research InstituteIRCCS Ospedale San Raffaele Milan Italy

7. Department of Urology Ludwig‐Maximilians‐University of Munich Munich Germany

8. Department of Urology La Croix du Sud Hospital Toulouse France

9. Institut Universitaire du Cancer Toulouse—Oncopole Toulouse France

10. Department of Urology University Hospital Hamburg‐Eppendorf Hamburg Germany

11. Martini‐Klinik Prostate Cancer Center University Hospital Hamburg‐Eppendorf Hamburg Germany

12. Department of Urology University Hospital‐Hamburg Eppendorf Hamburg Germany

13. Center of Urologic Surgery, Dialysis and Renal Transplantation Fundeni Clinical Institute Bucharest Romania

14. Department of Urology Sheba Medical CenterTel Hashomer, affiliated with Sackler Faculty of MedicineTel Aviv University Tel Aviv Israel

15. Oncology InstituteSheba Medical Center Tel‐Hashomer Israel

16. Division of Oncology/Unit of Urology Urological Research InstituteIRCCS Ospedale San Raffaele Milan Italy

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.4184

Reference30 articles.

1. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting

2. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

3. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial

4. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial

5. Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study;European Urology Oncology;2024-06

2. Comparison of Short-Term Outcomes and Safety Profiles between Androgen Deprivation Therapy+Abiraterone/Prednisone and Androgen Deprivation Therapy+Docetaxel in Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer;The World Journal of Men's Health;2024

3. A territory-wide real-world efficacy and toxicity analysis of abiraterone acetate versus docetaxel in 574 Asian patients with metastatic hormone-sensitive prostate cancer;Clinical Genitourinary Cancer;2023-08

4. Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic;Clinical Genitourinary Cancer;2023-04

5. Advancements in the treatment of metastatic hormone-sensitive prostate cancer;Frontiers in Oncology;2022-08-18